[1] Smyk D,Cholongitas E,Kriese S,et al. Pimary biliary cirrhosis:Family stories.Autoimmune Dis,2011,20（11）:189-192.
[2] Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology,2000,31（4）:1005-1013.
[3] Talwalkar JA,Lindor KD. Pimary biliary cirrhosis. Lancet, 2003,362（9377）:53-61.
[4] Selmi C,Affronti A,Ferrari L,et al. Immune-mediated bile duct injury:The case of primary biliary cirrhosis. World J Gastrointest Pathophysiol,2010,1（4）:118-128.
[5] Sfakianaki O,Koulentaki M,Tzardi M,et al. Perinuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. World J Gastroenterol,2010,16（39）:4938-4943.
[6] 李祥金,杨晋辉. 原发性胆汁性肝硬化AMA-M2阴性患者的临床及病理特点. 世界华人消化杂志,2009,17（16）:1676-1679.
[7] 姜慧英,刘妍. 原发性胆汁性肝硬化患者抗gp210抗体与核膜型抗核抗体的检测及其临床意义.中国实验诊断学,2010,14（11）：1796-1798.
[8] 姚光弼. 临床肝脏病学. 2版. 上海：上海科技出版社,2004:483-492.
[9] 杨江华,候为顺,喻艳林,等. 25例原发性胆汁性肝硬化患者临床和病理特征分析. 实用肝脏病杂志,2007,10（5）：315-317.
[10] 姚光弼. 中国人原发性胆汁性肝硬化的前瞻性研究.肝脏,2002,7（3）：146-149.
[11] Huet PM,Vincent C,Deslauriers J,et al. Portal hypertension in primary biliary cirrhosis（PBC）:A reversible condition Yes,but not in all UDCA treated patients. Hepatol Res,2009,39（10）:1032-1038.
[12] 张福奎,贾继东. 熊去氧胆酸治疗原发性胆汁性肝硬化. 肝脏,2007,12（3）：210-212.
[13] Poupon RE,Lindor KD,Parés A,et al.Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol,2003,39（1）:12-16. |
